GREY:BIOAF - Post by User
Comment by
prophetoffactzon May 23, 2023 8:12pm
261 Views
Post# 35461094
RE:They told you what they were going to do...
RE:They told you what they were going to do..."In my opinion, all of the wordings related to Biodexa becoming a therapeutic company and no longer being a drug delivery company served two purposes. The first was to articulate the Biodexa strategic plan. The second purpose, I suggest, was to implicitly reveal that drug delivery assets would no longer be needed or wanted at Biodexa, thus providing notice of and cover for the intended sale of the xB3 Platform into private hands after Bioasis was acquired by Biodexa."
Denali is a therapeutics company. Its name is Denali Therapeutics. Because Denali is a therapeutics company doesn't mean that it is in a nefarious scheme to sell its delivery technology off behind its shareholder's backs. Denali is developing an internal pipeline of therapeutics with its delivery technology. Biodexa wanted to develop xB3 therapeutics and had Hunter as its lead xB3 pipeline asset. Biodexa's glioblastoma asset was probably ultimately a prime target for xB3 too but that had a aways to go before clinical trials andprobably no data at the time of the proposed merger.
The market hasn't been interested in delivery technology companies. It's been the worst biotech bear market in hiistory. It wants the full net present value a drug. Therapeutics companies develop the full drug. The market hasn't had much interest in delivery technology a long ways from clinical trials. xB3 still has a way to go to clinical trials. That was a real problem. Rathjen tried to interest the market with Phase II ready assets with the acquisition of Cresence to get on NASDAQ. That wasn't enough and so she tried to add Midatech which is well into clinical trials. She got Armistice Capital's interest and US$10 million which would have got the company to hard milestones.